Ann: Amendment to ASX announcement - Zelira's diabetic nerve pai, page-2

The below quote was removed:

"Dr. Bryan Doner, DO, CHWS, FACHM, Lead Principal Investigator said:
As the lead principal investigator for the previous ZEL-007 clinical study, I am
delighted to successfully complete this groundbreaking clinical research and
the unveiling of its topline data analysis. The implications of these results for
patients are incredibly promising and thrilling.
Through this rigorously designed study, we have demonstrated that ZLT-L-007
is a safe, effective, and well-tolerated alternative for patients who would
typically seek a Lyrica® level of pain relief.
I am particularly pleased that the topline data reveals no reported serious
adverse events, and participants’ blood pressure and other safety vitals
remained unaffected throughout. This confirms that ZLT-L-007 is a well tolerated product that delivers statistically significant pain relief, surpassing
the levels achieved by Lyrica.®
These findings not only contribute to the advancement of research in the
cannabinoid pharmaceutical industry but also hold immense significance in
enhancing patient care by informing future studies and treatment optimisation."

GL